VivArt-X is developing a degradable biomaterial medical device designed to regenerate breast tissue and help transplanted fat survive better following tissue removal for breast cancer. The company's primary focus is on breast tissue regeneration, with plans to expand to additional applications over time. VivArt-X closed a €660,000 pre-seed round to accelerate and further develop a proof-of-concept. The technology aims to improve outcomes of reconstructive breast surgery, potentially reducing the need for repeat procedures. The company has been recognized with the Anton Gerard Award and the ESDP European Innovation Award and was a finalist of the Brabant40. CEO and founder Dan Jing Wu emphasized that the funding will speed research and contribute to addressing critical women's health issues.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2023